Researchers update understanding of damaging liver disease
A new article updates the medical community on a potentially devastating liver disease that afflicts approximately 29,000 Americans. Primary sclerosing cholangitis, or PSC, is a condition that damages the ducts that carry digestive bile from the liver to the small intestine. Many individuals affected by this disease eventually require a liver transplant for continued survival. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 22, 2016 Category: Science Source Type: news

Mayo Clinic researchers update understanding of damaging liver disease
ROCHESTER, Minn. — An article published today in the New England Journal of Medicine updates the medical community on a potentially devastating liver disease that afflicts approximately 29,000 Americans. Primary sclerosing cholangitis, or PSC, is a condition that damages the ducts that carry digestive bile from th e liver to the small intestine. Many individuals affected [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - September 21, 2016 Category: Research Source Type: news

Bile acid uptake inhibitor prevents nash/fatty liver in mice
Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists have shown. The findings suggest that these drugs, known as ASBT inhibitors, could be a viable clinical strategy to address NASH, an increasingly common liver disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 21, 2016 Category: Science Source Type: news

Sancilio withdraws $86m IPO for lipid-based drug delivery
Sancilio Pharmaceuticals last week withdrew its plans for an initial public offering it hoped would bring in $86 million for its Advanced Lipid Technology drug delivery platform. The Florida-based company registered the IPO in August 2015, but today requested that the SEC consent to its withdrawal, without giving a specific reason. The company’s drug delivery platform enables absorption of food in the absence of healthy intestines, bile or normal gastric enzymes, according to Sancilio. The ALT platform encapsulates its drugs in micelles – lipid molecules arranged in a sphere, with hydrophilic heads facing the surface t...
Source: Mass Device - September 19, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Initial Public Offering (IPO) Wall Street Beat Mylan Sancilio Pharmaceuticals TherapeuticsMD Source Type: news

Patient overcomes rare acute necrotizing pancreatitis
Larry Jacob got the call every parent fears. His daughter was sick, away at college and needed help. Mr. Jacob left his home in the Chicago suburbs and was driving to Western Illinois University when he suddenly doubled over in pain. He called an ambulance and was taken to a local hospital, where he was treated for pancreatitis, which is a painful condition most commonly caused by gallstones developing and becoming lodged in the bile duct. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 15, 2016 Category: Science Source Type: news

Albireo Appoints Dr. Paresh N. Soni as Chief Medical Officer
BOSTON, Sept. 08, 2016 -- (Healthcare Sales & Marketing Network) -- Albireo Limited, a clinical-stage company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver... Biopharmaceuticals, Gastroenterology, Personnel Albireo, bile acid modulator (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 8, 2016 Category: Pharmaceuticals Source Type: news

Declining Use of CBD Exploration in Choledocholithiasis Declining Use of CBD Exploration in Choledocholithiasis
Over the past 15 years, the use of open and laparoscopic common bile duct exploration in patients with choledocholithiasis has declined markedly, according to data from the National Inpatient Sample (NIS).Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 6, 2016 Category: Surgery Tags: General Surgery News Source Type: news

The Incredible Brain Of Simone Biles
Team USA gymnast Simone Biles twists and flips through air with a seemingly gravity-defying buoyancy. With great precision, she lands on the balance beam as if the 4-inch-wide ledge is an extension of her own body. As the 19-year-old gymnast competes in the Olympics in Rio de Janeiro this week, pulling out the types of combinations that have been repeatedly called “impossible,” you may ask what it is exactly that sets her apart — is it only practice? Or does Biles have a particular brain wiring that’s given her a repertoire of movements far beyond a human’s humble ability to walk str...
Source: Science - The Huffington Post - August 7, 2016 Category: Science Source Type: news

GLP-1 Analogues: Risk of Gallbladder Disease, Not Pancreatitis GLP-1 Analogues: Risk of Gallbladder Disease, Not Pancreatitis
Taking glucagon-like peptide 1 (GLP-1) analogues is associated with an increased risk of bile duct and gallbladder disease, but not pancreatitis, in people with type 2 diabetes, according to two new studies.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 3, 2016 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news

Newer Diabetes Drugs Could Boost Risk for Gallbladder and Bile Duct Disease (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Use of glucagon-like peptide 1 (GLP-1) receptor agonists is associated with increased risk for gallbladder and bile duct … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 1, 2016 Category: Primary Care Source Type: news

Two incretin-based drugs linked to increased bile duct disease but not pancreatitis
At least two incretin-based drugs – glucagon-like peptide 1 agonists and dipeptidyl peptidase 4 inhibitors – do not appear to increase the risk of acute pancreatitis in individuals with diabetes but... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - August 1, 2016 Category: Endocrinology Source Type: news

The Nerve to Believe in Our Kids
Last night my teenage daughter and I watched a thriller called Nerve, a new movie starring Emma Roberts and Dave Franco. Nerve portrays a world where young people chase after instafame by completing dares while a virtual audience watches. It also explores themes such as loss of privacy on social media and with games like Pokemon Go, and it shows how the online crowd veiled in anonymity can bring out bile, hate and shame. Watching young people like my daughter and her friends on their phones, one can easily give in to anxiety and imagine the next generation becoming a nation of drone like people tethered to devices. This is...
Source: Healthy Living - The Huffington Post - July 29, 2016 Category: Consumer Health News Source Type: news

Maintaining a healthy heart through bile acids
Groundbreaking research from the University of Alberta and McGill University has opened the door towards the future prevention of cardiac fibrosis -- a condition leading to heart failure for which there is currently no treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 27, 2016 Category: Science Source Type: news

Maintaining a healthy heart through bile acids
( < i > University of Alberta Faculty of Medicine & Dentistry < /i > ) Groundbreaking research from the University of Alberta and McGill University has opened the door towards the future prevention of cardiac fibrosis -- a condition leading to heart failure for which there is currently no treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 27, 2016 Category: Cancer & Oncology Source Type: news

FDA re-classifies Boston Scientific’s Wallflex biliary stent as Class II
The FDA said today it is reclassifying Boston Scientific‘s (NYSE:BSX) WallFlex Biliary RX fully covered stent system to a Class II device. The Marlborough, Mass.-based company submitted a request for reclassification on August 27 last year, according to the FDA release. The federal watchdog said it reviewed the request and determined the device viable to be classified as a Class II device with the establishment of “special controls,” which in addition to general controls will “provide reasonable assurance of the safety and effectiveness of the device.” Because the metallic biliary stent system...
Source: Mass Device - July 13, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Regulatory/Compliance Stents Boston Scientific Source Type: news